PDCL2 (Phosducin-like protein 2) is a member of the phosducin family, which plays roles in regulating G-protein signaling by interacting with βγ subunits of heterotrimeric G proteins. The PDCL2 gene encodes a protein predominantly expressed in immune tissues, such as the spleen and thymus, suggesting potential involvement in immune response modulation. Unlike its homolog PDCL3. PDCL2 exhibits tissue-specific expression and may influence cellular processes like protein folding, trafficking, or stress responses.
PDCL2 antibodies are essential tools for studying its expression, localization, and function. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research has linked PDCL2 to cancer progression, with studies showing altered expression in malignancies like hepatocellular carcinoma and gliomas. Antibodies against PDCL2 help elucidate its role in tumorigenesis, metastasis, or drug resistance mechanisms. Additionally, PDCL2 antibodies contribute to exploring interactions with molecular partners, such as chaperone proteins or signaling components, providing insights into its regulatory networks. Validated for specificity and sensitivity, these antibodies are critical for both basic research and potential diagnostic applications, bridging molecular biology with clinical oncology.